{"id":17414,"date":"2020-06-17T22:05:00","date_gmt":"2020-06-17T20:05:00","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=17414"},"modified":"2020-06-23T22:07:26","modified_gmt":"2020-06-23T20:07:26","slug":"isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/","title":{"rendered":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a>ISA Pharmaceuticals, a private clinical-stage immunotherapy company, plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo<sup>\u00ae<\/sup> (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The\nnew oropharyngeal cancer trial is the third trial planned under the clinical\ncollaboration between ISA Pharmaceuticals and Regeneron. ISA101b, an\nimmunotherapy targeting human papillomavirus type 16 (HPV16), is currently in a\nPhase 2 clinical trial for first- and second-line HPV16-positive head-and-neck\ncancer in combination with Libtayo, a PD-1 inhibitor that is being jointly\ndeveloped by Regeneron and Sanofi. A second Phase 2 trial investigating the\nsame combination in cervical cancer is also planned. More than 60 percent of\nhead-and-neck cancers and approximately 55 percent of cervical cancers are\nHPV16 induced.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under the revised\nagreement, the clinical collaboration offers a potential shortened\npath to first approval in the HPV16-positive oncology indications being studied\nin the next few years. The agreement also streamlines ISA Pharmaceuticals\u2019\naccess to license fees, milestone payments and royalties. Together with the\nrecently secured 20 million Euro loan from the European Investment Bank,\ndevelopment of ISA101b is now fully funded through the data readout of ongoing\nand planned pivotal trials which will support regulatory filings.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThis\nagreement will accelerate the development and commercialization of our lead\nasset, ISA101b, to treat two important cancers with high unmet medical needs.\u201d\ncommented<strong> Gerben Moolhuizen, Chief Executive Officer of ISA Pharmaceuticals<\/strong>.\u201cWe are extremely pleased to be working with Regeneron and for their\ncontinued support of both ISA Pharmaceuticals and our clinical studies in both\nindications.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Thanks to this updated clinical collaboration, we are able to rapidly diversify our research into a broader array of HPV16-induced cancers,\u201d said <strong>Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology, at Regeneron<\/strong>. \u201cISA101b offers a validated mechanism of action, and we look forward to working with ISA Pharmaceuticals to determine the synergistic potential of combining this novel immunotherapy with Libtayo to better address these difficult-to-treat cancers.\u201d <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: ISA Pharmaceuticals<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ISA Pharmaceuticals, a private clinical-stage immunotherapy company, plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo\u00ae (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals. The new oropharyngeal cancer trial is [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39,43],"tags":[],"class_list":["post-17414","post","type-post","status-publish","format-standard","hentry","category-gezondheid","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron - hollandbio\" \/>\n<meta property=\"og:description\" content=\"ISA Pharmaceuticals, a private clinical-stage immunotherapy company, plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo\u00ae (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals. The new oropharyngeal cancer trial is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-17T20:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-23T20:07:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron\",\"datePublished\":\"2020-06-17T20:05:00+00:00\",\"dateModified\":\"2020-06-23T20:07:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/\"},\"wordCount\":359,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\",\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/\",\"name\":\"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2020-06-17T20:05:00+00:00\",\"dateModified\":\"2020-06-23T20:07:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/","og_locale":"en_US","og_type":"article","og_title":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron - hollandbio","og_description":"ISA Pharmaceuticals, a private clinical-stage immunotherapy company, plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo\u00ae (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals. The new oropharyngeal cancer trial is [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/","og_site_name":"hollandbio","article_published_time":"2020-06-17T20:05:00+00:00","article_modified_time":"2020-06-23T20:07:26+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron","datePublished":"2020-06-17T20:05:00+00:00","dateModified":"2020-06-23T20:07:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/"},"wordCount":359,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid","Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/","name":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2020-06-17T20:05:00+00:00","dateModified":"2020-06-23T20:07:26+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/isa-pharmaceuticals-strengthens-strategic-immuno-oncology-collaboration-with-regeneron\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=17414"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17414\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=17414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=17414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=17414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}